# About Thymosin Alpha-1 Reviews: Who Publishes This Digest

> About this Thymosin Alpha-1 digest: Review TA1 is an independent editorial project summarizing the peer-reviewed thymic-peptide literature. Not a clinic, not a vendor, no medical advice.

An independent editorial reading of the thymic-peptide literature — what it is, and the lines it holds.

## What Review TA1 is

Review TA1 is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin Alpha-1 (the thymic peptide thymalfasin). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The 'reviews' in our name describes a position we occupy relative to the literature — an evidence-appraisal desk — not a claim to review, recommend, or supply anything.

## How we read the record

We lead with what each study measured and attribute it to its source. We grade the evidence honestly: the mechanism work is detailed, the chronic-hepatitis and immune-restoration signals are the most consistent, and the largest, most rigorous sepsis trial — phase-3 TESTS — was null. We hold the distinction between 'studied and approved abroad' and 'not approved in the United States' with discipline, and we keep Thymosin Alpha-1 correctly framed as an immune peptide, never as an anabolic, growth, or performance compound. We are careful not to confuse it with thymosin beta-4 / TB-500, thymulin, thymopentin, thymalin, or its precursor prothymosin alpha — each a distinct molecule.

## What this site does not do

We do not recommend doses, courses of treatment, or self-administration. Where we report figures from trials, they appear strictly as research data — by population and route — never as instructions to any reader. We do not name foreign brand products. We do not sell, source, or broker the peptide, and we carry no vendor links. Anyone considering anything described here should speak with a qualified clinician; this digest is for understanding the published science, nothing more.

---

A register of record on the thymic immune peptide thymosin alpha-1 — every claim logged to its study, the largest sepsis trial's null result kept in plain view, and not one thing here a clinic, a prescription, or for sale.